Orasure ( (OSUR) ) has released its Q2 earnings. Here is a breakdown of the information Orasure presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
OraSure Technologies, Inc., a leader in point-of-need and home diagnostic tests and sample management solutions, operates in the healthcare sector, focusing on improving access and quality of healthcare through innovative testing and sample management solutions.
In its latest earnings report for the second quarter of 2025, OraSure Technologies reported a significant decline in total net revenues, primarily due to a sharp decrease in COVID-19 related revenues. Despite this, the company remains focused on expanding its product portfolio and enhancing its commercial reach under new leadership.
Key financial highlights include a 43% decrease in total net revenues to $31.2 million, with core business revenues slightly declining by 5%. The company reported a GAAP operating loss of $18.0 million, compared to a loss of $2.7 million in the same quarter last year. OraSure also launched the HEMAcollect™ PROTEIN product, aimed at transforming proteomic research, and renewed its agreement with GeneDx to support early diagnosis of rare pediatric diseases.
Looking ahead, OraSure Technologies is preparing to launch several new products and is confident in its ability to achieve growth in 2026. The company’s strong balance sheet provides the flexibility to invest in opportunities that leverage existing capabilities for long-term growth.